[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634836":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":10,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Chengdu Kangnuoxing Biopharma,Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Group of Stapokibart Injection",null,[12],"Biological: Stapokibart",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"BIOLOGICAL","Stapokibart","subcutaneous injection",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Qian Jia","CONTACT","028-88610620","clinicaltrial@keymedbio.com",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Peking University People's Hospital","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":34,"coordinates":35},"Point",[36,37],116.39723,39.9075,{"lat":37,"lon":36},[40],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100634836","a-study-of-stapokibart-injection-in-patients-with-atopic-dermatitis-ad-100634836",false,"NCT07544862","A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)","A Prospective Study of Stapokibart Injection in Patients With Moderate-to-Severe Atopic Dermatitis (AD)","Inclusion Criteria:\n\n* Trial participants aged 18 years or older at baseline, with no restrictions on gender.\n* Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.\n\nExclusion Criteria:\n\n* Known history of allergic reaction to Stapokibart Injection.\n* Trial participants currently or plan participating in any interventional clinical trial.\n* Trial participants with hematologic malignancies.\n* Women with pregnant.\n* Any condition that, in the opinion of the investigator, may interfere with trial participants' ability to participate in the study.","ALL","18 Years",{"count":53,"type":54},1000,"ESTIMATED","52 Weeks","OBSERVATIONAL","This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.",[59],"Atopic Dermatitis (AD)","2026-06-08",{"date":62,"type":63},"2026-06-10","ACTUAL",{"date":65,"type":63},"2026-06-02",{"date":67,"type":54},"2028-02",{"name":5,"class":6},1]